Francis Pike1, Raghavan Murugan2, Christopher Keener1, Paul M Palevsky3, Anitha Vijayan4, Mark Unruh5, Kevin Finkel6, Xiaoyan Wen2, John A Kellum7. 1. The Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennyslvania; The CRISMA (Clinical Research, Investigation, and Systems Modeling of Acute illness) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania; 2. The Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennyslvania; The CRISMA (Clinical Research, Investigation, and Systems Modeling of Acute illness) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 3. The Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennyslvania; Renal Section, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania; 4. Division of Renal Diseases, Washington University, St. Louis, Missouri; 5. The CRISMA (Clinical Research, Investigation, and Systems Modeling of Acute illness) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Division of Nephrology, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico; and. 6. Division of Renal Diseases and Hypertension, University of Texas Medical School at Houston, Houston, Texas. 7. The Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennyslvania; The CRISMA (Clinical Research, Investigation, and Systems Modeling of Acute illness) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; kellumja@ccm.upmc.edu.
Abstract
BACKGROUND AND OBJECTIVES: Higher plasma concentrations of inflammatory and apoptosis markers in critically ill patients receiving RRT are associated with RRT dependence and death. This study objective was to examine whether plasma inflammatory (IL-6, -8, -10, and -18; macrophage migration inhibitory factor) and apoptosis (death receptor-5, tumor necrosis factor receptor I and II) biomarkers augment risk prediction of renal recovery and mortality compared with clinical models. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Biologic Markers of Recovery for the Kidney study (n=817) was a prospective, nested, observational cohort study conducted as an ancillary to the Veterans Affairs/National Institutes of Health Acute renal failure Trial Network study, a randomized trial of intensive versus less intensive RRT in critically ill patients with AKI conducted between November 2003 and July 2007 at 27 Veterans Affairs- and university-affiliated centers. Primary outcomes of interest were renal recovery and mortality at day 60. RESULTS: A parsimonious clinical model consisting of only four variables (age, mean arterial pressure, mechanical ventilation, and bilirubin) predicted renal recovery (area under the receiver-operating characteristic curve [AUROC], 0.73; 95% confidence interval [95% CI], 0.68 to 0.78) and mortality (AUROC, 0.74; 95% CI, 0.69 to 0.78). By contrast, individual biomarkers were only modestly predictive of renal recovery (AUROC range, 0.55-0.63) and mortality (AUROC range, 0.54-0.68). Adding plasma IL-8 to a parsimonious model augmented prediction of recovery (AUROC, 0.76; 95% CI, 0.71 to 0.81; P=0.04) and mortality (AUROC, 0.78; 95% CI, 0.73 to 0.82; P<0.01) compared with the clinical model alone. CONCLUSIONS: This study suggests that a simple four-variable clinical model with plasma IL-8 had predictive value for renal recovery and mortality. These findings require external validation but could easily be used by clinicians.
BACKGROUND AND OBJECTIVES: Higher plasma concentrations of inflammatory and apoptosis markers in critically illpatients receiving RRT are associated with RRT dependence and death. This study objective was to examine whether plasma inflammatory (IL-6, -8, -10, and -18; macrophage migration inhibitory factor) and apoptosis (death receptor-5, tumornecrosis factor receptor I and II) biomarkers augment risk prediction of renal recovery and mortality compared with clinical models. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Biologic Markers of Recovery for the Kidney study (n=817) was a prospective, nested, observational cohort study conducted as an ancillary to the Veterans Affairs/National Institutes of Health Acute renal failure Trial Network study, a randomized trial of intensive versus less intensive RRT in critically illpatients with AKI conducted between November 2003 and July 2007 at 27 Veterans Affairs- and university-affiliated centers. Primary outcomes of interest were renal recovery and mortality at day 60. RESULTS: A parsimonious clinical model consisting of only four variables (age, mean arterial pressure, mechanical ventilation, and bilirubin) predicted renal recovery (area under the receiver-operating characteristic curve [AUROC], 0.73; 95% confidence interval [95% CI], 0.68 to 0.78) and mortality (AUROC, 0.74; 95% CI, 0.69 to 0.78). By contrast, individual biomarkers were only modestly predictive of renal recovery (AUROC range, 0.55-0.63) and mortality (AUROC range, 0.54-0.68). Adding plasma IL-8 to a parsimonious model augmented prediction of recovery (AUROC, 0.76; 95% CI, 0.71 to 0.81; P=0.04) and mortality (AUROC, 0.78; 95% CI, 0.73 to 0.82; P<0.01) compared with the clinical model alone. CONCLUSIONS: This study suggests that a simple four-variable clinical model with plasma IL-8 had predictive value for renal recovery and mortality. These findings require external validation but could easily be used by clinicians.
Authors: Nattachai Srisawat; Xiaoyan Wen; Minjae Lee; Lan Kong; Michele Elder; Melinda Carter; Mark Unruh; Kevin Finkel; Anitha Vijayan; Mohan Ramkumar; Emil Paganini; Kai Singbartl; Paul M Palevsky; John A Kellum Journal: Clin J Am Soc Nephrol Date: 2011-07-14 Impact factor: 8.237
Authors: Zoltán H Endre; John W Pickering; Robert J Walker; Prasad Devarajan; Charles L Edelstein; Joseph V Bonventre; Christopher M Frampton; Michael R Bennett; Qing Ma; Venkata S Sabbisetti; Vishal S Vaidya; Angela M Walcher; Geoffrey M Shaw; Seton J Henderson; Maryam Nejat; John B W Schollum; Peter M George Journal: Kidney Int Date: 2011-02-09 Impact factor: 10.612
Authors: Sevag Demirjian; Glenn M Chertow; Jane Hongyuan Zhang; Theresa Z O'Connor; Joseph Vitale; Emil P Paganini; Paul M Palevsky Journal: Clin J Am Soc Nephrol Date: 2011-09 Impact factor: 8.237
Authors: Paul M Palevsky; Jane Hongyuan Zhang; Theresa Z O'Connor; Glenn M Chertow; Susan T Crowley; Devasmita Choudhury; Kevin Finkel; John A Kellum; Emil Paganini; Roland M H Schein; Mark W Smith; Kathleen M Swanson; B Taylor Thompson; Anitha Vijayan; Suzanne Watnick; Robert A Star; Peter Peduzzi Journal: N Engl J Med Date: 2008-05-20 Impact factor: 91.245
Authors: Katja M Gist; Jonathan Kaufman; Eduardo M da Cruz; Robert H Friesen; Sheri L Crumback; Megan Linders; Charles Edelstein; Christopher Altmann; Claire Palmer; Diana Jalal; Sarah Faubel Journal: Pediatr Crit Care Med Date: 2016-04 Impact factor: 3.624
Authors: Jaclyn R Daniels; Jennie Z Ma; Zhijun Cao; Richard D Beger; Jinchun Sun; Laura Schnackenberg; Lisa Pence; Devasmita Choudhury; Paul M Palevsky; Didier Portilla; Li-Rong Yu Journal: Kidney360 Date: 2021-11-25
Authors: Melanie Meersch; Mira Küllmar; Christoph Schmidt; Joachim Gerss; Toni Weinhage; Andreas Margraf; Thomas Ermert; John A Kellum; Alexander Zarbock Journal: J Am Soc Nephrol Date: 2017-12-01 Impact factor: 10.121
Authors: Jason H Greenberg; Michael Zappitelli; Yaqi Jia; Heather R Thiessen-Philbrook; Christina A de Fontnouvelle; F Perry Wilson; Steven Coca; Prasad Devarajan; Chirag R Parikh Journal: J Am Soc Nephrol Date: 2018-02-22 Impact factor: 10.121